Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

is of safety and efficacy to be conducted based on predefined criteria. Kosan anticipates providing more information on the TIME-1 trial design upon initiation.

The TIME-2 clinical trial is being conducted at clinical sites primarily in the US and in Europe and is designed to enroll approximately 130 patients with relapsed-refractory multiple myeloma. The trial is designed to test three different doses of tanespimycin in combination with the approved dose and schedule of bortezomib (Velcade(R)) (1.3 mg/m2). The tanespimycin dose groups are 50 mg/m2, 175 mg/m2 and 340 mg/m2. Tanespimycin will be administered twice weekly as a one-hour intravenous infusion on a cycle of two weeks of treatment every three weeks (the same schedule as bortezomib). Patients eligible to participate in the TIME-2 trial must have been treated with and progressed following at least three prior treatments for multiple myeloma. Prior regimens must include bortezomib and lenalidomide (Revlimid(R)). The primary endpoint of the trial is the dose response based on objective response rate after 4 cycles of treatment. Secondary endpoints include a comparison of response rate between the three dose groups, progression-free survival, time to treatment failure and overall survival. Objective response rate in multiple myeloma is measured primarily by the patient's level of M protein.

About the Special Protocol Assessment

As stated in the Prescription Drug User Fee Act (PDUFA) and FDA's Guidance for Industry Special Protocol Assessment, "...having agreed to the design, execution, and analyses proposed in protocols reviewed under this process ... the Agency will not later alter its perspective on the issues of design, execution, or analyses unless public health concerns unrecognized at the time of protocol assessment under this process are evident. Thus, documented special protocol assessments should be considered binding on the review division and should not be changed at any time..." as
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... -- Decision Resources, one of the world,s leading ... healthcare issues, finds that over 70 percent of ... need for diabetes drugs with novel mechanisms of ... a high need for additional DPP-IV inhibitors. Both ... glucose lowering ability and physicians in particular say ...
(Date:12/17/2009)... Make-A-Wish Foundation announced today that it will receive ... ® Wishes charitable public ... on the tradition of blowing on an eyelash ... launched earlier this year to raise awareness and ... excitement around the availability of LATISSE® (bimatoprost ophthalmic ...
(Date:12/16/2009)... of national medical societies launched a multi-state advertising campaign ... Affordable Care Act, currently under consideration by the U.S. ... in the coming days. The groups are targeting ... care bill that is "bad medicine" for patients. ... system needs reform - but the current Senate health ...
Breaking Medicine Technology:Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 2Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 3The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 2The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 3The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 4The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 5Physician Groups Oppose Current Senate Health Care Reform Bill 2Bills Address Long Waits for Behavioral Health Patients 50063 1Bills Address Long Waits for Behavioral Health Patients 50063 2Bills Address Long Waits for Behavioral Health Patients 50063 3MIT is pleased to announce that it has received a US 24 500 000 private placement from its Chinese partners 12787 1MIT is pleased to announce that it has received a US 24 500 000 private placement from its Chinese partners 12787 2NTU receives 242 7 million research funds for innovative water quality monitoring technologies 50055 1NTU receives 242 7 million research funds for innovative water quality monitoring technologies 50055 2
(Date:12/17/2009)... lull in the outbreak is a good time to ... 17 (HealthDay News) -- As the current wave of ... on Thursday urged that everyone get vaccinated in case ... shortages of the H1N1 flu vaccine have eased, it,s ... and Human Services Secretary Kathleen Sebelius said during a ...
(Date:12/17/2009)... medical information using virtually any smart phone , ... ... Skyscape, Inc., the world’s most trusted source for medical information ... mobile clinical decision application on the Google Android operating system. ... phone devices, making the ability for medical professionals to download ...
(Date:12/17/2009)... YORK, Dec. 17 Reportlinker.com announces ... available in its catalogue: ,, India ... to 2015 ,, http://www.reportlinker.com/p0169911/India-Healthcare-IT-Investment-Opportunities-Analysis-and-Forecasts-to-2015.html ... and Forecasts to 2015 ,, Summary ... source for in-depth information and data relating ...
(Date:12/17/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, http://www.reportlinker.com/p0169972/Top-Ten-Worlds-Leading-Life-Science-Intermediates-Companies.html ... competitive environment is widely recognized as ... responsibilities, the task crucial to business ... factual competitive intelligence is vital to ...
(Date:12/17/2009)... 17 Today, CDC,s Morbidity and Mortality ... the number of state-level epidemiologists has decreased steadily ... 10% since 2006. There was also a substantial ... period, including epidemiology capacity for bioterrorism and emergency ... such as occupational health, substance abuse, and oral ...
Breaking Medicine News(10 mins):Health News:Swine Flu Wanes, But Future Uncertain 2Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 2Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 3Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 4Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 2Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 3Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 4Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 5Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 6Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 7Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 8Health News:Reportlinker Adds Top Ten World's Leading Life Science Intermediates Companies 2Health News:CSTE National Assessment Finds Critical Public Health Disease Surveillance Capacity Lacking 2
... pink and blue condoms have flooded downtown Toronto. But talking ... world's largest// AIDS conference. ,"Fear of AIDS will ... like the anti-smoking drives which everyone ignores," Yvonne Green, an ... be able to talk about sexual pleasure in public. Without ...
... study published in the British Medical Journal, researchers at Oxford ... per cent in the consumption of common foods// containing trans ... in coronary heart disease. ,Trans fats are added ... is added to most fast foods, confectionary, sandwich spreads, and ...
... sexual activities among young teens as well as delay ... according// to a recent study of the controversial HIV ... 6 and 7 students from inner-city middle schools in ... taught an abstinence-only approach to sex had lower chances ...
... victims will be tabled by the Union Health Ministry ... light of the XVI International AIDS Conference, Union Health ... because we wanted some amendments to the draft and ... be tabled in Parliament in the winter session." ...
... may be more appropriate in men with low-risk prostate ... or radiation therapy, according to a research// team at ... ,The results of the study conducted by lead researcher ... published in the Journal of the National Cancer Institute. ...
... new maple syrup diet sweeping through Britain and promoted by pop star ... days.// ,All over the country, health shops are seeing ... star Beyonce Knowles said she used it to shed the pounds for ... made from the sap of maple and palm trees and costs about ...
Other Medicine News:Health News:Safe Sex and Good Sex is the Talk of AIDS Conference 2Health News:HIV Prevention through Abstinence-only Programs 2Health News:Legislation to Prevent Discrimination against HIV/AIDS Victims 2Health News:Watchful Waiting Effective for Low Risk Prostate Cancer 2
... Professional Diagnostics is a leading provider of ... DFA test menu that includes kits for ... well as miscellaneous conjugates and components. Our ... wide assortment of substrates and kit sizes ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... Professional Diagnostics is a leading provider of ... DFA test menu that includes kits for ... well as miscellaneous conjugates and components. Our ... wide assortment of substrates and kit sizes ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
Medicine Products: